

DARPA-SN-26-91
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID)

Task Area-4: Commercialization and Sustainment

Frequently Asked Questions

Version 1
June 19, 2026

Clarifications

- The Task Areas (TAs) are not subgroupings of tasks expected to be accomplished by one performer. TA-3 and TA-4 are not continuations of TA-1 and TA-2 but separate tasks areas that will be running concurrently to support the clinical, regulatory, commercialization, and manufacturing aspects of RAPIID. TA-3 is not a further development TA for TA-1 components and TA-2 devices. All TAs will be active in both phases of the program. TA-1 and TA-2 performers cannot apply to TA-3 and/or TA-4.
- We use Arabic numerals (Phase 1 and Phase 2) for the phases of the RAPIID program and Roman numerals (Phase I and II) when discussing clinical trial phases.
- The Food & Drug Administration (FDA) is an independent Government agency that is not a participant in the RAPIID program. DARPA will defer to FDA on regulatory matters as this is the mandate for their Agency.
- Technology Readiness Levels (TRLs) relevant to the RAPIID program are defined here:
 - [Link to Integrated Technology Readiness Levels For Medical Countermeasure Products \(Drugs and Biologics\)](#)
 - [Link to TECHNOLOGY READINESS LEVELS FOR MEDICAL COUNTERMEASURE PRODUCTS \(DIAGNOSTICS AND MEDICAL DEVICES\)](#)

Administrative, Legal, and Financial Questions

Contracting & Budget

1. **Q:** The Special Notice references the \$2M accelerated award option threshold described in HR001126S0003, and the TA-1/TA-2 FAQ (Q19) states that DARPA does not have anticipated budget ceilings for those task areas. Does DARPA have a target funding range or ceiling for TA-4, Phase 1?

A: No, DARPA does not have anticipated budget ceilings or target funding ranges. The cost proposal should accurately reflect the costs needed to complete the proposed technical work. Cost proposals will be evaluated following the “Cost and Schedule Realism” evaluation criteria described in Section 4. The accelerated award option was included to maintain alignment with the overall BTO Office-wide notice award mechanism and should not be construed as a target ceiling/funding range.

2. **Q:** For purposes of scoping the TA-4 effort and developing the ROM, can DARPA provide an anticipated number of TA-1 and TA-2 performers that the TA-4 performer would be expected to support during Phase 1?

A: For the purposes of budgeting and generating a ROM budget, please use a total of 10 performers. The exact number of performers is currently unknown and is subject to change. Using this estimated number of performers should not be construed as a guaranteed or anticipated number of awards that will be made under DARPA-PS-26-124.

Eligibility

3. **Q:** As used in the solicitation, FAQ (e.g., Q42, Q82), and Special Notice, does the term "performer" and all subsequent references to it refer to any entity or individual potentially receiving funding under the OT agreement, including subcontractors, vendors, and consultants to a prime recipient? Or does "performer" refer only to the prime recipient of the OT agreement? This distinction is relevant to understanding the scope of the OCI restrictions between TA-1/TA-2 and TA-3/TA-4.

A: The term "performer" refers to all personnel who will be completing work under the OT award, including but not limited to subawardees, vendors, and consultants. Please see Section 4.2 in [DARPA-PS-26-124](#), available on sam.gov, for more details and rationale regarding Conflicts of Interest and Organizational Conflicts of Interest.

4. **Q:** I am planning to apply for TA-3 and/or 4 and was contacted by someone planning to apply to TA-1 and/or 2 to be part of their team. Does this make me ineligible for TA-3 and/or 4 funding?

A: Yes. Organizations or individuals awarded funding under TA-1 and/or TA-2 are explicitly prohibited from receiving awards for TA-3 and/or TA-4 due to Conflicts of Interest between the Task Areas. Please see Section 4.2 in [DARPA-PS-26-124](#), available on sam.gov, for more details and rationale regarding Conflicts of Interest and Organizational Conflicts of Interest.

General Proposal

5. **Q:** Section 3.2 states that abstracts must follow the content guidelines as described in Attachment A, however there is a discrepancy between the contents of DARPA-SN-26-91 and the contents of Attachment A. Which format should we follow?

A: Submitted abstracts for DARPA-SN-26-91 should follow the length and content information described in the Special Notice rather than Attachment A. See Sections 3 of the Special Notice for that information. Potential proposers should use Attachment A as a template, though.